Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans

The mitogen-activated protein kinase (MEK) inhibitor zapnometinib is in development to treat acute viral infections like COVID-19 and influenza. While the antiviral efficacy of zapnometinib is well documented, further data on target engagement/pharmacodynamics (PD) and pharmacokinetics (PK) are need...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Julia Koch-Heier, Annika Schönsiegel, Lara Maria Waidele, Julian Volk, Yvonne Füll, Christian Wallasch, Sebastian Canisius, Michael Burnet, Oliver Planz
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2022-06-01
סדרה:	Frontiers in Pharmacology
נושאים:	MEK inhibitor pharmacokinetic pharmacodynamic antiviral therapy zapnometinib WES
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fphar.2022.893635/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!